A new medical marijuana market is emerging in the United States, but it will not be one of the world’s biggest.
Medical marijuana is a legal plant used to treat a wide range of medical conditions including epilepsy, fibromyalgia, and multiple sclerosis.
However, unlike its recreational counterparts, it is not regulated, and it is illegal to grow it for any purpose.
This means that medical marijuana is not a viable option for those looking to cash in on the drug.
There are also concerns about its potency, with some researchers estimating that it is only as potent as 10mg per gram.
To cater for this, medical marijuana dispensaries are being set up in a number of US cities, with an expected influx of investors.
The company that is currently leading the charge is Merrimack Pharmaceuticals, an American company that specialises in producing cannabis extracts and concentrates.
The firm has plans to open five stores across the country by the end of this year, and a further three in California by the middle of next year.
The move comes just weeks after US President Donald Trump signed an executive order banning marijuana, with cannabis legalisation likely to be included in his second budget proposal.
The US President has previously said that the federal government should not interfere with states’ rights, and Merrimacks new move is a sign that he may be ready to reverse course.
According to Merrimacked, its US cannabis products will include extracts of THC (tetrahydrocannabinol), cannabidiol (CBD), cannaridol (CBN), cannavarone (CBT), cannopropyl betaine (CPB), cannstatin (CPP), cannucin (CVC), cannumimide (CNV), and other products.
It also plans to create an online marketplace for medical marijuana products and to offer educational materials and training.
In addition, Merrimackers products will be distributed through pharmacies in New Jersey, Pennsylvania, New York, Massachusetts, Michigan, Ohio, Wisconsin, and Pennsylvania.
This is not the first time that Merrimacking has stepped into the US medical marijuana space.
In 2015, the company began selling cannabis oil through its website.
However the company has been in the news in the past few years for a number reasons, most notably for the seizure of a large amount of its cannabis oil.
In 2016, the Federal Trade Commission accused MerrimACK of engaging in deceptive marketing practices, including the distribution of the product through a pharmacy, without a prescription.
In September 2016, Merrisons chief executive officer, Joe Salvanto, resigned following allegations that he had lied to investors.
He has since been appointed by the Trump administration as a senior adviser to the White House Office of Management and Budget.
Sources: Sportmedia.it, sportmedia, medjesus, medical, medusa